USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
NRG Therapeutics, a privately-held UK-based neuroscience company targeting mitochondrial dysfunction, has received a Biomedical Catalyst (BMC) award from the UK government. 30 May 2022
British targeted medicine company Redx Pharma has raised a total of £35 million ($43 million) in a share placement, with both new and existing institutional investors participating in the funding round. 19 May 2022
In the USA, the National Institute of Allergy and Infectious Diseases (NIAID) has awarded $67.5 million to a consortium of researchers working on pandemic preparedness. 19 May 2022
Investment company eureKARE, which is focused on financing and building biotech companies in the disruptive fields of synthetic biology and the microbiome, has announced the emergence of eureKING. 12 May 2022
US start-up biotech MOMA Therapeutics, which is discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced the completion of a $150 million Series B financing. 10 May 2022
In a striking vote of confidence from big pharma, British targeted protein degradation (TPD) specialist Amphista Therapeutics has inked two strategic collaborations with major drug developers. 5 May 2022
Tubulis, a Munich-based biotech company in the antibody drug conjugate (ADC) space, has announced the successful closing of a 60 million euros ($63 million) series B financing round. 4 May 2022
Coming out of stealth since its founding in 2019, US biotech Dianthus Therapeutics today announced the completion of its $100 million Series A financing led by 5AM Ventures, Avidity Partners, and Fidelity Management & Research Company. 3 May 2022
India continues to establish itself as the pharmacy of the world as exports swell by 103% since 2013-14. The pharmaceutical industry is now being urged to work toward becoming the healthcare custodian of the world by adhering to good manufacturing practices, reports The Pharma Letter’s India correspondent. 3 May 2022
British charity Cancer Research UK has launched a new project aimed at driving forward innovation in the development of oncology medicines. 28 April 2022
Data and analytics company GlobalData has found that the UK has a thriving oncology-focused startup and venture capital (VC) scene compared to its European neighbors. 26 April 2022
US biotech Apertura Gene Therapy today announced that it has launched with a Series A financing of up to $67 million from Deerfield Management Company to develop genetic medicines using platform technologies that address key limitations of genetic medicine delivery and expression. 26 April 2022
UK biotech Forcefield Therapeutics has launched to develop drugs to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction. 25 April 2022
Research from industry analyst GlobalData has highlighted the limited impact that Western sanctions have had on foreign innovator drugs in Russia. 22 April 2022
US biotech firm Tessera Therapeutics, which is pioneering a new approach in genetic medicine known as GENE WRITING technology, has raised over $300 million in Series C financing. 21 April 2022
USA-based Satellite Bio has emerged from stealth to reveal its ‘Tissue Therapeutics’ that are bioengineered to repair, restore or replace critical organ or tissue function. 20 April 2022
Boston, USA-based Sionna Therapeutics, a life sciences company founded in 2019 to develop highly effective and differentiated treatments for cystic fibrosis (CF), has announced the official launch of the company and the closing of a $111 million Series B financing. 20 April 2022
USA-based BioXcel Therapeutics, a biopharma using artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, has announced strategic financing agreements with funds managed by Oaktree Capital Management and Qatar Investment Authority (QIA). 19 April 2022
In a filing with the US Securities and Exchange Commission (SEC), Boston-based rare disease specialist Imara has disclosed savage job cuts as part of an extensive restructuring. 19 April 2022
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news